Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes – Trading Markets (press release)

Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
Trading Markets (press release)
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.